Sarepta疗法 SRPT 深 沪
已收盘 02-06 16:00:00 美东时间
18.50
+1.470
+8.63%
华盛通- 最 高18.635
- 今 开17.59
- 成交量 317.36万股
- 最 低 17.512
- 昨 收 17.03
- 总市值 19.39亿
- 52周最高 110.00
- 市盈率 静 7.91
- 换手率 3.03%
- 52周最低 10.415
- 委 比 77.97%
- 总股本 1.05亿
- 历史最高 181.83
- 量 比 1.04
- 振 幅 6.59%
- 历史最低 0.433
- 每 手 1
- 风险率 28.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BUZZ-U.S. STOCKS ON THE MOVEx-IDEX Corp, Union Pacific, Qualcomm
BUZZ-U.S. STOCKS ON THE MOVEx-IDEX Corp, Union Pacific, Qualcomm Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500, Nasdaq and the Dow fell, as the market still grappled wi
02-05 02:42
Sarepta Therapeutics Gets New Zealand Approval For Its Clinical Study Application For SRP-1005-101
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, has granted approval for
02-04 21:33
U.S. RESEARCH ROUNDUP-AMETEK, Stryker, Zimmer Biomet Holdings
U.S. RESEARCH ROUNDUP-AMETEK, Stryker, Zimmer Biomet Holdings Jan 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AMETEK, Stryker and Zimmer Biomet Holdings, on Tuesday. HIGHLIGHTS * AMETEK AME.N : Oppenheimer cuts to
01-27 15:49
Sarepta Says Elevidys Slows Duchenne Progression After Three Years
Sarepta's Elevidys shows significant improvement in motor function measures after three years of treatment, with no new safety signals.
01-26 22:26
UPDATE 1-Sarepta's Duchenne gene therapy slows disease progression, three-year data shows
UPDATE 1-Sarepta's Duchenne gene therapy slows disease progression, three-year data shows Adds shares in paragraph 2, details throughout Jan 26 (Reuters) - Sarepta Therapeutics' SRPT.O gene therapy for a progressive muscle‑wasting disorder showed sustained benefit in patients' ability to control and
01-26 21:24
Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows
Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows Jan 26 (Reuters) - Sarepta Therapeutics' SRPT.O gene therapy for a progressive muscle‑wasting disorder showed sustained benefit in patients' ability to control and coordinate movement, according to three‑year data f
01-26 21:07
美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价
今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元
01-26 14:32
Sarepta jumps on upcoming release of 3-year Elevidys data
Sarepta Therapeutics (SRPT) is up ~10% in after-hours trading Friday after announcing it will release topline, 3-year results from its EMBARK study of Elevidys (delandistrogene moxeparvovec) in Duchen...
01-24 06:55
BRIEF-Sarepta Therapeutics To Report 3-Year Topline Data From Embark Study Of Elevidys Gene Therapy
BRIEF-Sarepta Therapeutics To Report 3-Year Topline Data From Embark Study Of Elevidys Gene Therapy Jan 23 (Reuters) - Sarepta Therapeutics Inc SRPT.O : SAREPTA THERAPEUTICS TO REPORT 3-YEAR TOPLINE DATA FROM EMBARK STUDY OF ELEVIDYS GENE THERAPY IN AMBULATORY INDIVIDUALS WITH DUCHENNE MUSCULAR DYST
01-24 05:43
Wedbush Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $34
Wedbush analyst Yun Zhong maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price target from $32 to $34.
01-23 22:00
